Three Canadian Researchers Receive Sanofi–CARO Award for Research in Prostate Cancer Therapies

July 3, 2018, Toronto, ON – The Canadian Association of Radiation Oncology (CARO) and Sanofi Canada are pleased to announce three CARO members have been awarded the Sanofi-CARO Awards!

$20,000 to Ning-Ning Lu for her project: Feasibility and Toxicity of mp-MRI guided focal SABR with or without whole gland SABR for patients with localized prostate cancer.

$14,000 to Michael Tjong for his project: Prospective Validation of a Novel-Voxel- and Machine Learning-based Automated Planning Method for Prostate Fossa Volumetric Arc Radiotherapy.

$14,000 to Juanita Crook, Transcriptional Mapping of Immune -Tumor-Vasculature Cell Interactions in Response to HDR Brachytherapy.

These unrestricted research grants will play an essential role in continuing their research in prostate cancer therapies. They were made possible through funding by Sanofi Canada.

Dr. David Petrik, the Sanofi-CARO Awards Panel Chair, described “The Sanofi-CARO Awards are an opportunity to fund innovative projects.  The funded projects often lead to larger endeavours and help to support ongoing Canadian research on prostate cancer therapies.”

Dr. Michael Brundage, CARO President, remarked “The support of Sanofi research awards is critical to the success of each of these three projects, which together represent novel and important advances in external-beam and brachytherapy treatments for Canadian men diagnosed with prostate cancer.”

“The need for new cancer medicines remains great, and Sanofi is committed to helping address this need,” says Dr. Sophia Kajla, Medical Head for General and Established Medicines, Sanofi Canada.  “With our strong heritage in oncology, we are proud to support the research of Canadian radiation oncology clinicians and researchers to develop new treatments for prostate cancer that will help improve patients’ lives.” 
2018 Sanofi–CARO Awards:

These research projects were chosen for funding on the basis of their high scientific merit, feasibility and relevance to Canadian radiation oncology. The funds awarded must be spent within Canada.

Advances in therapy offer hope to patients and their families. By supporting such projects, it confirms a commitment to ongoing research and innovation to find solutions that improve quality of life; and even prolong it. 
About the Canadian Association of Radiation Oncology
The Canadian Association of Radiation Oncology (CARO) – Association canadienne de radio-oncologie (ACRO) is a not-for-profit association with the mandate to represent and support its membership nationally and internationally, through the promotion of high standards of patient care in the practice of radiation oncology, support of excellence in professional standards, and the promotion of radiation oncology research and education. CARO is a partner with other disciplines in seeking to improve outcomes for cancer patients, and provides a consultative authority to oncology related agencies, academic institutions, and to the public in all matters pertaining to radiotherapy and oncology in Canada. For further information:

About Sanofi
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
Sanofi entities in Canada employ approximately 1,900 people. In 2017 we invested $123 million in R&D in Canada, creating jobs, business and opportunity throughout the country.

Follow us on Twitter @SanofiCanada and on YouTube.

Sanofi, Empowering Life

For further information:

Danielle Smith
Senior Association Coordinator

Sanofi Canada
Nadia Rahman
Communications, Sanofi Canada